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Abstract 
In the next decades, the number of older people will rise substantially in Germany. 
Likewise, drug treatment and polypharmacy will also augment due to the high prevalence 
of multimorbidity in this subpopulation. Since older people are often excluded from 
randomized controlled trials prior to drug approval, pharmacoepidemiological safety 
studies (PSS) based on spontaneous reporting systems and electronic healthcare 
databases often represent the only opportunity to investigate the safety of drugs in this 
population. However, these studies have specific methodological challenges related to the 
clinical characteristics of older patients and the nature of the data sources. Thus, the 
overall aim of this thesis is to (1) critically assess methodological challenges of PSS 
based on spontaneous reporting systems and electronic healthcare databases with a 
focus on older patients and (2) to define further areas of research to enhance their quality.  
In this context, disproportionality analyses based on spontaneous reports, cohort studies, 
nested case-control studies, and case-only designs are introduced as study designs for 
PSS. Confounding (e.g., by frailty), outcome and exposure misclassification as well as 
time-related biases in PSS are illustrated as selected methodological challenges. These 
challenges are then discussed in the context of my research articles with a focus on older 
people, and opportunities to address these challenges are presented. More specifically, 
the role of spontaneous reporting systems in the detection of adverse drug reactions in 
older people is critically assessed. Afterwards, drug utilization studies as well as the 
application of high-dimensional propensity score methods and case-only designs are 
discussed as options to overcome the specific problem of confounding by indication and 
unmeasured confounding in PSS among older people. Further, a detailed review of the 
patient’s profile is recommended to increase the specificity of the outcome case-
algorithms in administrative claims databases. Moreover, it is highlighted that sensitivity 
analyses in drug utilization and safety studies are particularly important in the case of “as-
needed” treatment among older patients and if information on the prescribed daily dose is 
missing. Finally, it is highlighted how time-related biases can be prevented in cohort and 
nested-case-control studies using a time-dependent analysis and risk-set sampling, 
respectively. In the conclusion, future research perspectives with regard to PSS in older 
patients are pointed out as, for instance, the use of semi-automated drug safety 
monitoring based on electronic healthcare databases, the availability of additional medical 
information in the context of the German “e-health” legislation or the need for external 
validation studies to study the impact of outcome and drug exposure misclassification.   
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1. Preface 
This doctoral thesis was prepared based on several research articles attached in the 
appendix. The following sections are intended to integrate the content of these research 
articles into an overall public health context.  
The following research articles are part of this doctoral thesis: 
1. Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal 
leukoencephalopathy for immunosuppressants: a disproportionality analysis of 
spontaneous reports within the US Adverse Event Reporting System (AERS). 
Pharmacoepidemiology and Drug Safety 2012 Nov;21(11):1216-20. 
doi: 10.1002/pds.3320 
In this article, we investigated safety signals of progressive multifocal 
leukoencephalopathy (PML) for different immunosuppressants based on spontaneous 
reports of possible adverse drug reactions in the U.S. Adverse Event Reporting System. 
Our analyses revealed signals of PML for several immunosuppressants including drugs 
previously not considered as potential risk factors for PML, e.g., azathioprine and 
cyclosporine. 
2. Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous 
 thromboembolism in elderly patients with dementia. Journal of Clinical 
 Psychopharmacology 2013;33:753-8. 
doi: 10.1097/JCP.0b013e3182a412d5 
This article describes a nested case-control study based on the German 
Pharmacoepidemiological Research Database (GePaRD) in which we investigated 
whether the use of antipsychotics is associated with a higher risk of venous 
thromboembolism (VTE) in older patients with dementia. We found a higher risk of VTE 
for current users of antipsychotics in general and users of combination therapy of 
conventional and atypical antipsychotics compared to non-use. Among current users, the 
risk of VTE was only elevated for new users, i.e., during the first three months of 
treatment.  
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3. Ohlmeier C, Langner I, Hillebrand K, Schmedt N, Mikolajczyk R, Riedel O, Garbe 
E. Mortality in the German Pharmacoepidemiological Research Database 
(GePaRD) compared to national data in Germany: results from a validation study. 
BMC Public Health 2015;15:570. 
doi: 10.1186/s12889-015-1943-7 
In this study, we compared mortality figures from GePaRD with external data from the 
Federal Statistical Office of Germany. We observed diverging mortality rates in several 
federal states that might result from the higher socioeconomic status of the study 
population in GePaRD compared to the overall population in Germany. In Bremen, where 
the socioeconomic representativeness is higher for GePaRD, the mortality rates were in 
good accordance with external data. In addition, the agreement of the percentage of 
hospital deaths in both data sources suggests completeness of outpatient mortality 
information in GePaRD. 
4. Schmedt N, Jobski K, Kollhorst B, Krappweis J, Rüther E, Schink T, Garbe E. 
Treatment patterns and characteristics of older antipsychotic drug users in 
Germany. International Clinical Psychopharmacology 2016 May;31(3):159-69.  
doi: 10.1097/YIC.0000000000000119 
In this study, we explored the characteristics and treatment patterns of older antipsychotic 
users in Germany based on GePaRD. We found that most antipsychotics were frequently 
used for indications other than schizophrenia and bipolar disorders, e.g., dementia, 
depression, pain, vertigo or nausea. In addition, the baseline prevalence of co-morbidities 
and co-medications substantially differed for users of individual drugs. The observed low 
persistence in combination with a high number of treatment episodes suggests frequent 
“as-needed” treatment with antipsychotics, especially in patients with dementia. In 
general, this study can serve as a reference for drug utilization studies in other countries 
and provides important information for comparative safety studies in older antipsychotic 
users. 
5. Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E, Schink T. 
Comparative risk of death in older adults treated with antipsychotics: a population-
based cohort study. European Neuropsychopharmacology 2016 Jul 27. doi: 
10.1016/j.euroneuro.2016.07.006. [Epub ahead of print]  
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In this cohort study, we compared the risk of death in older patients initiating treatment 
with 15 different antipsychotics in Germany based on GePaRD. Since previous analyses 
indicated substantial differences for users of individual antipsychotics (Schmedt et al. 
2016a), we also applied high-dimensional propensity score methods to further explore the 
potential for confounding. In summary, we found that the use of haloperidol, 
zuclopenthixol, and melperone is associated with an increased risk of death compared to 
risperidone. The same applies for the use of levomepromazine and chlorprothixene in 
patients aged 80 years and older and in those with dementia. While the slightly increased 
risk of death for melperone requires further investigation, our study suggests that 
haloperidol, zuclopenthixol, levomepromazine, and chlorprothixene should be avoided in 
older patients except in palliative care as long as other treatment options exist.
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Further authored and co-authored research articles and “letters to the editor” dealing with 
the evaluation of drug safety after marketing approval are related to and cited in this 
thesis. 
  
1. Amann U, Schmedt N, Garbe E. Prescribing of potentially inappropriate 
medications for the elderly: an analysis based on the PRISCUS list. Deutsches 
Arzteblatt international 2012;109:69-75. 
 doi: 10.3238/arztebl.2012.0069 
In this study, we explored the frequency of use of potentially inappropriate medications for 
older adults in Germany based on criteria of the PRISCUS list before its publication. The 
study highlights the need for drug safety studies in older drug users due to a frequent use 
of medications that might be associated with adverse drug reactions in this population.  
2. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated 
 with antipsychotics: role of alpha1 adrenoceptor affinity. Journal of Clinical 
Psychopharmacology 2010 Feb;30(1):68-71 
 doi: 10.1097/JCP.0b013e3181c8273d 
The analyses described in this article were based on spontaneous reports of possible 
adverse drug reactions from the U.S. Food and Drug Administration. With this data, we 
conducted a disproportionality analysis and explored whether safety signals of priapism 
arose for antipsychotics depending on their alpha1 adrenoceptor affinity. As one article of 
this thesis (Schmedt et al. 2012) is based on the same data source, and disproportionality 
analyses of spontaneous reports are discussed as a tool to generate hypotheses of 
possible adverse drug reactions after marketing approval, this study is cited as another 
example of this method. 
3. Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E. Injury 
prevention by medication among children with attention-deficit/hyperactivity 
disorder: a case-only study. JAMA Pediatrics 2015 Apr;169(4):391-5. 
 doi:10.1001/jamapediatrics.2014.3275 
In this article, we investigated whether treatment with methylphenidate and atomoxetine 
can prevent injuries among children with attention-deficit/hyperactivity disorder using the 
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self-controlled case series design. Since this case-only design is discussed as an option 
to prevent unmeasured confounding in drug safety studies, it is cited as an example of this 
methodological approach.   
4. Schmedt N, Garbe E. Letter by Schmedt and Garbe regarding article, "statins and 
the risk of cancer after heart transplantation". Circulation 2013;127:e440. 
 doi: 10.1161/CIRCULATIONAHA.112.135707 
5. Schmedt N, Azoulay L, Hense S. Re.: "Reduced risk of lung cancer with 
metformin therapy in diabetic patients: a systematic review and meta-analysis". 
American Journal of Epidemiology 2014;180:1216-7. 
 doi: 10.1093/aje/kwu311
In these “letters to the editor”, we pointed out that immortal time bias and time-window 
bias may have led to an overestimation of the beneficial effects of statins with regard to 
the occurrence of cancer after heart transplantation and of metformin regarding the risk of 
lung cancer in patients with diabetes. Since these forms of biases may also affect drug 
safety studies and can result in substantially biased study results, the “letters to the editor” 
are cited as examples. 
In addition, some parts are based on unpublished analyses within the 
“Pharmacoepidemiological Safety Study of Neuroleptics and Antidepressants in the Area 
of Geriatric Psychiatrics (PhaSiNAg)” conducted at the Leibniz Institute for Prevention 
Research and Epidemiology – BIPS and funded by the Federal Institute for Drugs and 
Medical Devices. In this study, I was the project manager and epidemiologist. 
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2. Introduction 
According to the 13th population projection of the Federal Statistical Office in Germany, 
the number of people aged 65 years and older will rise from 17 million in 2013 to 23 
million in 2037 reflecting a relative increase of approximately 40%. The strongest relative 
elevation is expected for those aged 80 years and older with an 124% increase from 4 
million in 2013 to 10 million in 2050 (Federal Statistical Office 2015). Since multimorbidity 
is prevalent in many older people and increases with rising age (Barnett et al. 2012, 
Marengoni et al. 2011), drug treatment and polypharmacy are likely to rise substantially in 
the next decades. In 2013, patients aged 65 years and older already received 55% of all 
“Defined Daily Doses” (DDDs) of drugs prescribed to members of German statutory health 
insurance providers (SHIs), although they represented only 22% of the total population 
(Schaufler and Telschow 2014). Compared to data from 2007, the total number of 
prescribed DDDs in this age group increased by 24% within 6 years (own calculations 
based on Coca and Nink 2008 and Schaufler and Telschow 2014).  
Against this background, the evaluation of beneficial and especially of harmful drug effects 
in older patients is of high public health interest and will become even more important in 
the future. Although older patients may be particularly prone to serious adverse drug 
reactions (ADRs), they are often excluded from randomized controlled trials (RCTs) prior 
to drug approval due to restrictive inclusion criteria (e.g., Herland et al. 2005). Therefore, 
studies based on spontaneous reporting systems and electronic healthcare databases 
often represent the only opportunity to investigate the safety of drug use in this population 
after marketing approval (Garbe and Pigeot 2015, Garbe and Suissa 2014). Similar to 
pharmacoepidemiological studies in other subpopulations such as children or pregnant 
women, the evaluation of drug safety in older patients poses specific methodological 
challenges. Some of them refer to the clinical characteristics of older patients, others are 
related to the nature of the data sources. 
Thus, the overall aim of this thesis is to (1) critically assess methodological challenges of 
pharmacoepidemiological safety studies (PSS) based on spontaneous reporting systems 
and electronic healthcare databases with a focus on older patients and (2) to define 
further areas of research to enhance their quality. Since four of five research articles 
included in this thesis are based on data from GePaRD, most discussions primarily focus 
on this data source. 
The first part of this thesis provides important background information on the need for 
drug safety studies after marketing approval, data sources for drug safety studies and 
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specific aspects of drug use in older patients. Thereafter, the objectives are defined 
followed by a section briefly illustrating study designs available for drug safety studies and 
selected methodological challenges. Based on this, I discuss how these challenges can 
affect drug safety studies with a focus on older patients and how they can be addressed. 
In conclusion, future perspectives of research in this field are pointed out. 
3. Background 
3.1. Need for Drug Safety Studies after Marketing Approval 
3.1.1. Legal Requirements for Drug Approval in Germany 
From 1956 to 1961, thalidomide (Contergan®) was sold in Germany as a nonbarbiturate 
hypnotic sedative. At the time, the production and approval of drugs were not regulated for 
pharmaceutical companies in Germany and testing for possible harmful effects was not 
routinely undertaken in humans prior to drug marketing (Rehman et al. 2011). In 1961, 
Contergan® was withdrawn from the market by the manufacturer due to accumulated 
case reports of congenital malformations in newborns whose mothers had been exposed 
to the drug during pregnancy (Maio 2001). Later, it became clear that more than 10,000 
malformed children were born worldwide due to exposure to Contergan® (Franks et al. 
2004).  
As a result of this tragedy, drug marketing and approval in Germany was increasingly 
regulated in the following years ending with the commencement of the second 
Pharmaceutical Drug Act in 1976, which is still in place in an updated version today. The 
key regulations of this law include requirements with regard to consistency, production 
and quality of the drug, drug approval, protection of humans in clinical trials, collection and 
analysis of drug-related risks, and liability in case of ADRs. Further, the quality, safety, 
and efficacy of a drug have to be demonstrated in appropriate studies before approval 
taking into account the respective directives of the European Union (Andersohn 2011).  
According to the legal prerequisites, new drugs are investigated in preclinical animal and 
in vitro studies and in three phases of clinical trials in humans prior to marketing approval 
(Garbe and Suissa 2014). In phase I, a small number of individuals is exposed to the 
respective drug in order to obtain first information on tolerability as well as 
pharmacodynamic and pharmacokinetic aspects in humans. Phase II studies usually 
include several hundreds of patients and serve to define the appropriate dose range of the 
drug and to obtain first information on its efficacy and safety within the target population. 
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Last, phase III studies are mostly conducted as RCTs to prove the efficacy of the drug and 
to monitor possible ADRs compared to placebo or commonly used treatment alternatives 
in larger patient populations (approx. 1,000 to 3,000 persons) (Garbe and Suissa 2014).  
3.1.2. Limitations of Randomized Controlled Trials 
Pre-marketing RCTs provide important information on the efficacy and safety of drugs and 
efforts for drug approval are commonly terminated if ADRs are detected in these studies 
(Schuster et al. 2005). Nevertheless, many drugs are withdrawn after a long time on the 
market and after many patients have used them. Between 1980 and 2009, one out of 
seven newly approved drugs was later withdrawn by the U.S. Food and Drug 
Administration. Approximately 22% of withdrawals were related to safety concerns, i.e., 
3.5% of all drugs approved during this period were withdrawn due to safety reasons 
(Qureshi et al. 2011). These withdrawals are the result of several limitations of RCTs prior 
to marketing approval. 
First, the sample sizes of RCTs are usually not large enough to detect elevated risks of 
rare ADRs. For instance, a sample size of approximately 23,500 patients would be 
required per study arm to find a twofold increased risk of a drug compared to a reference 
group for an outcome with an incidence of 1 per 1,000 allowing for a beta error of 20% 
(Garbe and Suissa 2014). Since the assumed relative risk of an ADR in users of a specific 
drug compared to a reference category and the incidence of ADRs are usually much 
smaller, rare but severe ADRs can often not be identified in these studies.  
Second, findings from RCTs usually cannot be extrapolated to routine care. Even phase 
III studies mostly have very restrictive inclusion criteria analyzing study populations who 
are not representative for subsequent drug users in clinical practice. Frequently, pregnant 
women, children, patients with severe co-morbidity, and especially older patients are not 
included or at least under-recruited (Garbe and Suissa 2014). For instance, Herland et al. 
(2005) showed that only 5.4% of a population with asthma from clinical practice and 17% 
with chronic obstructive pulmonary disease would fit into the restrictive criteria routinely 
used in RCTs.  
Third, phase I to III trials are conducted under experimental conditions in specialized units 
by well-trained staff. Thus, study participants are closely monitored and treatment in 
clinical trials follows a standardized regimen for which adherence is tightly controlled. 
However, poor medication adherence and large treatment variations depending on 
individual patient characteristics and response to therapy are common in clinical practice 
(Garbe and Suissa 2014). This especially applies to older patients in whom medication 
10 
adherence may be lower in the case of polypharmacy (Pasina et al. 2014) and for whom 
many drugs are initiated at a lower dose and slowly up-titrated (Wehling and Burkhardt 
2013). 
Fourth, RCTs usually have a short follow-up which impedes the detection of so-called 
“type D ADRs” with a long induction period or occurring after cumulative drug exposure, 
e.g., vaginal adenocarcinoma after exposure to diethylstilbestrol during pregnancy or 
tardive dyskinesias after treatment with antipsychotics (Edwards and Aronson 2000).  
For all these reasons, possible harmful effects of drugs have to be further investigated 
intensively after marketing approval. 
3.2. Data Sources for Drug Safety Studies 
3.2.1.  Case Reports and Spontaneous Reporting Systems 
Once a drug has been approved and is available on the market, several data sources can 
be used for post-marketing surveillance of its safety profile. The first is the assessment of 
case reports of possible ADRs published in the literature or sent to the responsible 
authorities by health professionals, consumers or manufacturers. Case reports of possible 
ADRs can be evaluated qualitatively based on established criteria for causality 
assessment (e.g., World Health Organization 2016a) or quantitatively using different 
statistical methods for so-called disproportionality analyses as soon as they have been 
entered into spontaneous reporting systems (Almenoff et al. 2007, Bate and Evans 2009). 
Information on case reports of possible ADRs usually include age, sex, suspected drugs 
and co-medication, the date of initiation and discontinuation of drug treatment, date and 
severity of the possible ADR, underlying indications for drug treatment, etc. In Germany, 
the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich Institute collect 
and analyze spontaneous reports of possible ADRs (Federal Institute for Drugs and 
Medical Devices 2016, Paul-Ehrlich Institute 2016) which are also combined for analyses 
on the supranational level by the European Union (European Medicines Agency 2016) 
and the World Health Organization (World Health Organization 2016b). The U.S. Food 
and Drug Administration gathers spontaneous reports from the United States and other 
countries, which are freely available on the internet for research purposes (U.S. Food and 
Drug Administration 2016). Although the assessment of case reports is particularly 
important for the detection of rare ADRs and is recognized as a useful tool to generate 
hypotheses about unknown ADRs at an early stage after marketing approval, the analysis 
of case reports is prone to various types of biases (see section 6.1). In addition, it is not 
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possible to determine risks of ADRs due to underreporting, stimulated reporting, and 
missing denominator information on individuals exposed to the drug, and the data quality 
of spontaneous reports is often poor (Garbe and Suissa 2014). Therefore, other data 
sources such as field studies or electronic healthcare databases have to be used to 
conduct PSS of higher quality to investigate the safety profile of newly approved drugs in 
the real world setting. 
3.2.2. Primary vs. Secondary Data 
Data sources for PSS after marketing approval can be subdivided into primary data 
gathered in field studies and secondary data mostly obtained by health insurance 
providers for reimbursement purposes or available as electronic medical records from 
general practitioners or hospitals (Strom 2012).  
Field studies have significantly contributed to the knowledge of ADRs of drugs after 
marketing approval, e.g., with regard to the risk of VTE associated with the use of oral 
contraceptives (Lewis et al. 1997, Spitzer et al. 1996), and they are often conducted 
based on multi-purpose cohorts such as the Women’s Health Initiative Study (Bavry et al. 
2014, Desai et al. 2013). Other examples of PSS based on primary data are the Berlin 
Case-Control Surveillance Study (Andersohn et al. 2004) as well as studies from the 
pharmacovigilance center “Embryotox” (Weber-Schoendorfer and Schaefer 2016) or the 
German biologic registry (Strangfeld and Zink 2014). Even though field studies have to be 
considered a valuable tool for specific research questions, PSS based on secondary data 
have recently become more popular. Since their first use in the 1980s in North America, 
large electronic healthcare databases have increasingly been established worldwide 
(Strom 2012). This development did not occur by chance, but can be attributed to the 
advantages of using secondary data compared to primary data. An overview and a 
comparison of the characteristics of primary and secondary data for PSS are shown in 
Table 1. 
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Table 1 Comparison of primary and secondary data for pharmacoepidemiological studies 
(modified from Andersohn and Garbe 2008) 
Characteristic Primary data Secondary data 
Number of study participants Lower High 
Time required for the study High Lower 
Costs of the study High Lower 
Calculation of the incidence of rare 
events possible 
Mostly not Yes 
Study enrollment of patients with severe 
diseases possible 
Mostly not Yes 
Exposure information of over-the-
counter drugs available 
Yes No 
Recall bias possible Yes No 
Interview bias possible Yes No 
Selection bias due to non-response 
possible 
Yes No 
Information on life-style-related factors 
(e.g., alcohol consumption, smoking, 
physical activity) available   
Yes 
Mostly not 
(partly in medical 
record databases) 
Laboratory test results and other clinical 
parameters available 
Yes 
Mostly not 
(partly in medical 
record databases) 
Information on disease severity 
available 
Yes Mostly not 
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As described above, the outcomes of interest are usually rare events which could not be 
investigated adequately in pre-marketing RCTs, and PSS often require a very large 
sample size of 10,000 exposed persons or more combined with a respective control group 
of the same or larger size. Field studies of this size would be very time consuming and 
expensive. In contrast, studies based on electronic healthcare databases can be 
conducted much faster and are more cost-efficient, since the data have already been 
collected. Since safety issues usually need to be investigated rapidly to address 
regulatory and public health crises, electronic healthcare databases are often considered 
the preferred data source for PSS after marketing approval (Strom 2012). A further 
advantage of secondary data is that they include data of populations rarely investigated in 
RCTs or extremely difficult to acquire for field studies, e.g., older persons living in nursing 
homes or patients with distinct multimorbidity. For these patients, information on drug 
exposure is assumed to be complete for most drugs in electronic healthcare databases, 
whereas its collection is prone to recall or interviewer bias in field studies (Schneeweiss 
and Avorn 2005). On the other hand, electronic healthcare databases also have 
disadvantages compared to field studies, since they often lack information on possible 
important confounders in PSS (e.g., smoking, alcohol consumption or physical activity), 
and the validity of diagnoses used for identification of outcome events may be limited 
(Strom 2012). In field studies, confounder information can already be considered at the 
stage of data collection and the occurrence of the outcome can be assessed according to 
previously defined clinical definitions.  
3.2.3.  Administrative Claims vs. Medical Record Databases 
As mentioned above, there is a large amount of electronic healthcare databases for PSS 
after marketing approval worldwide. These include different types of databases depending 
on the health care system in which they were generated. They are usually categorized 
into administrative claims databases and medical record databases (Strom 2012).  
Administrative claims data typically appear when individuals use the health care system, 
e.g., when they receive drug dispensations, require hospital care or contact registered 
physicians in ambulatory care. In many health care systems, these services are paid for 
by health insurance providers or the state. For reimbursement purposes and quality 
control, specific information on these services is documented electronically. Commonly, 
data on pharmacy dispensations, hospital data, and ambulatory care data are reported to 
the patient’s health insurance provider and can be used together with available 
sociodemographic information in PSS. In other cases, records from different areas of care 
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and registries (e.g., death or birth registries) are available and can be linked by an unique 
identifier (Strom 2012). 
Medical record databases were developed more recently than administrative claims 
databases and are a consequence of the increasing computerization of documentation in 
medical practices and hospitals (Strom 2012). Two well-known examples are the Clinical 
Practice Research Datalink (CPRD) (Herrett et al. 2015) and the Health Improvement 
Network (THIN) (Hall 2009). Both databases from the United Kingdom primarily include 
medical records from ambulatory care; however, information on hospitalizations has been 
recently made available via linkage (Herrett et al. 2015).  
Administrative claims databases have the advantage that they usually include data from 
all sites of care needed for PSS, i.e., pharmacy dispensations, hospitalization, and 
ambulatory care. Since the identity of the drug and the dispensed amount of the drug 
define the price for reimbursement, pharmacy claims are subject to high standards of 
quality control and can therefore be assumed to provide very accurate data (Schneeweiss 
and Avorn 2005, Strom 2012). The same applies for hospital data mostly reimbursed 
based on Diagnosis Related Groups (DRGs) and thus relying on appropriate coding of 
diagnoses. However, concerns have been raised regarding the practice of upcoding of 
diagnoses by hospitals to receive the largest possible payment (Lüngen and Lauterbach 
2000). A major limitation of administrative claims data is often related to the validity of 
ambulatory diagnoses because their correct coding does not influence the physician’s 
payment and consequently there is no incentive for correct coding in contrast to hospital 
data (Strom 2012). Compared to administrative claims data, medical record databases 
include very detailed information on diagnostic data from ambulatory care, but data from 
other physicians and other sites of care, especially hospital diagnosis data and dates of 
hospitalization, may be incomplete or missing if only data from the general practitioner are 
entered into the system (Andersohn and Garbe 2008).  
3.2.4. Secondary Data in Germany  
In Germany, secondary data from various sources are available for public health research 
purposes. The majority of Germans are insured with an SHI, whereas private health 
insurance providers are only accessible to a small proportion, i.e., to employees with an 
income higher than 56,250€1 and specific occupational groups as for instance self-
                                               
1 income threshold for compulsory health insurance in 2016 assessed at 
https://www.bundesregierung.de/Content/DE/Artikel/2015/10/2015-10-14-sozialversicherung.html 
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employed persons or civil servants. In 2014, 70.3 out of 81.2 million people in Germany 
(approx. 87%) were members of one of the 118 different SHIs, including 15.5 million 
members aged 65 years and older (Federal Ministry of Health 2016). Secondary data 
available from the SHIs for research purposes mainly comprise sociodemographic data, 
hospital data, ambulatory care data, and outpatient drug dispensing data, but also data on 
medical devices as well as dentist and nursing care data (Swart et al. 2014). However, the 
use of secondary data in Germany is strongly regulated by law. According to § 75 of the 
Social Act X, social data can be delivered for research purposes only if the public health 
interest of the project substantially outweighs data privacy concerns of the individuals. All 
research projects based on pseudonymized data from SHIs have to be approved by the 
respective SHI and the responsible authority (e.g., the German Federal Insurance Office 
for Germany-wide acting SHIs) (Garbe and Pigeot 2015).  
Since four of five research articles included in this thesis were based on GePaRD, its 
characteristics and structure are introduced in more detail. 
GePaRD was established by the Leibniz Institute for Prevention Research and 
Epidemiology – BIPS and currently consists of administrative claims data from four SHIs 
with information on about 20 million people. Thus, it represents nearly 25% of the German 
population from all federal states of Germany. The database comprises sociodemographic 
core data, hospital data, outpatient dispensation data, and outpatient care data of all 
individuals enrolled in one of the four SHIs since 2004. Sociodemographic core data 
contain information on sex, year of birth, insurance status, and reason for deregistration 
from the SHI. Hospital data comprise the date of admission and discharge, different types 
of diagnoses (admission, main discharge, secondary and ancillary diagnoses), diagnostic 
and therapeutic procedures, and the reason for hospital discharge (incl. death). Data from 
outpatient physician visits incorporate diagnoses on a quarterly basis including the 
diagnostic certainty (assured, suspected, excluded, and status post diagnosis), and types 
and dates of diagnostic and therapeutic procedures. All diagnoses are coded according to 
the German Modification of the 10th revision of the International Classification of Diseases. 
Dispensation data contain information on prescriptions dispensed in a pharmacy and 
reimbursed by the respective SHI. Drugs purchased over the counter and most of the 
medications administered in hospitals are not contained in GePaRD. Dispensation 
information also includes the dates of the prescription and dispensation, the number of 
prescribed packages, the specialty of the prescribing physician, and the central 
pharmaceutical number of the drug. Based on a pharmaceutical reference database, 
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information on the generic and brand name of the drug, packaging size, strength, DDD, 
and other pharmaceutical information can be linked to GePaRD (Garbe et al. 2011, Pigeot 
and Ahrens 2008).  
3.3. Drug Use in Older Patients 
Clinical pharmacology investigates the response to and the effect of drug treatment on the 
individual level while pharmacoepidemiology aims to measure the effects of drug 
treatment on the population level using epidemiological methods. In other words, 
pharmacoepidemiology is the application of epidemiological methods to clinical 
pharmacology (Hennessy 2006). From a pharmacological point of view, each application 
of a drug to a patient has to be regarded as a single experiment with an unknown 
outcome depending on individual characteristics of the patient and the correct application 
of the drug (Wehling and Burkhardt 2013). Several factors may influence the 
pharmacological response to a drug and may lead to substantial variation of drug effects 
in single patients. This has to be taken into account in the interpretation of PSS and 
especially applies to older patients. The most important factors in this context are reduced 
physiological resources or frailty leading to alterations in pharmacokinetics and 
pharmacodynamics as well as multimorbidity accompanied by polypharmacy and resulting 
drug interactions. In the following, the most important factors with a possible impact on 
individual treatment outcomes in older patients are described in more detail. In addition, 
the PRISCUS list and other criteria defining potentially inadequate medication in older 
patients are introduced.  
3.3.1.  Alterations in Pharmacodynamics and Pharmacokinetics 
In clinical pharmacology, the study of drugs is usually subdivided into pharmacodynamics 
and pharmacokinetics. While pharmacodynamics concern the biochemical and 
physiological effects of the drug on the human body, pharmacokinetics focus on the 
process of absorption, distribution, and elimination of the drug in the human body 
(Hennessy 2006). In older patients, physiological changes typically occurring during the 
aging process or mediated by co-morbidity can cause alterations of pharmacodynamics 
and pharmacokinetics. The major concern in this context is usually an elevated plasma 
concentration causing possible drug toxicity and ADRs, especially for drugs with a narrow 
therapeutic window, e.g., cardiac glycosides or several anti-epileptics frequently used in 
older patients (Turnheim 2003, Turnheim 2004).  
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Pharmacokinetic alterations with increasing age are well understood and seem to have a 
greater impact on the variability of drug effects in older patients compared to 
pharmacodynamics. The most critical aspect is the accumulation of the drug due to 
reduced clearance from the body which might also lead to toxicity and ADRs. Impaired 
clearance is mainly caused by a reduced glomerular filtration rate for drugs being 
eliminated via the kidneys (“renal clearance”) and a reduced hepatic blood flow or 
decreased capacity of enzymes for drugs being first metabolized in the liver (“hepatic 
clearance”) (Wehling and Burkhardt 2013).  
The glomerular filtration rate usually declines with increasing age due to an elevated 
failure of nephrons, but its reduction can also be triggered by co-morbidity such as 
atherosclerosis or type 2 diabetes mellitus. Renal clearance of a specific patient generally 
depends on age, weight, sex, and plasma creatinine concentration as a measure of renal 
function (Wehling and Burkhardt 2013). In contrast to hepatic clearance, it can be 
calculated easily in a “bed-side” approach by the physician using for instance the 
Cockcroft and Gault formula (Cockcroft and Gault 1976). One frequent mistake is that 
physicians only use the plasma creatinine concentration as a measure for renal clearance, 
although both formation and elimination of creatinine are reduced in older patients. This 
results in normal plasma creatinine concentration even in case of an impaired glomerular 
filtration rate (Turnheim 2003). It is estimated that this phenomenon accounts for 
approximately 25 percent of all preventable ADRs (Wehling and Burkhardt 2013).  
While renal elimination mainly affects water soluble drugs, many other lipid soluble drugs 
cannot be eliminated via the kidneys and have to be transferred into water soluble 
products first. This metabolism is usually performed in the liver and catalyzed by the so-
called cytochrome P450 (CYP) isoenzymes. Besides frequent genetic polymorphisms of 
these enzymes, hepatic disease, reduced hepatic blood flow due to other age-related 
diseases as, for instance, heart failure and a generally reduced activity of CYP 
isoenzymes can lead to drug toxicity due to diminished metabolism of the drug in older 
patients (Wehling and Burkhardt 2013). Since hepatic clearance may work despite severe 
liver disease, it is still an uncommon cause of impaired clearance compared to a reduced 
glomerular filtration rate (Hennessy 2006). Other factors that might lead to variations in 
drug responses in older patients involve the absorption and the distribution of the drug but 
are considered to have minor impact compared to renal and hepatic elimination and are 
therefore not further discussed here (Hennessy 2006, Turnheim 2003).  
The effect of age on pharmacodynamics has not been well investigated and is more 
difficult to analyze compared to pharmacokinetics. Probably, physiological changes and 
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age-induced alterations in target-structures of the drug, e.g., with regard to the number of 
receptors, as well as impaired homeostatic regulation are responsible for different 
responses to drugs and a higher risk of ADRs in older patients (Hennessy 2006). One 
important example is the increased sensitivity of some older patients to benzodiazepines 
leading to strong sedative effects even at a very low dose which may partly be related to 
disturbed circadian rhythm and reduced nerve conduction velocity (Wehling and Burkhardt 
2013).  
In summary, impaired renal elimination in first instance and secondly reduced hepatic 
metabolism may lead to a higher risk of drug toxicity in older patients. In the interpretation 
of PSS, it is important to recognize that older patients may vary substantially with regard 
to physiological alterations meaning that responses to drugs and their beneficial and 
unintended effects will be even more heterogeneous than in younger populations.  
3.3.2.  Multimorbidity, Polypharmacy, and Drug Interactions 
Increasing age is accompanied by a higher prevalence of age-related disease and 
multimorbidity (Barnett et al. 2012) constituting a major challenge for drug treatment, 
especially if more than one physician is involved in the care of the same patient. If other 
co-morbidity and co-medication is not adequately considered, several drugs are 
administered concomitantly which might lead to drug interactions and increased risks of 
ADRs (Wehling and Burkhardt 2013). Typical ADRs resulting from drug interactions are 
neuropsychological syndromes, hypotension with related falls as well as acute renal 
failure (Mallet et al. 2007). The occurrence of ADRs not recognized by physicians might 
lead to “prescribing cascades”, i.e., additional polypharmacy by the initiation of further 
drugs to treat unrecognized ADRs (Rochon and Gurwitz 1997).  
Drug interactions can occur on the level of pharmacodynamics and pharmacokinetics. On 
the one hand, different drugs may compete for the same target structures, e.g., for the 
same receptor group which might lead to increased plasma concentrations of the drugs. 
On the other hand, drug interactions may emerge in the hepatic metabolism of the drugs if 
two or more substrates are metabolized by the same CYP isoenzyme or if drugs act as 
inducers or inhibitors of specific CYP isoenzymes. This can result in enhanced or 
diminished metabolism, reduced efficacy or possibly toxicity (Hennessy 2006, Turnheim 
2003). An overview of possible interactions during hepatic metabolism via CYP 
isoenzymes can be derived from the Flockhart list (Flockhart 2011).  
Although not all drug-drug interactions have clinical relevance and lead to ADRs, their 
prevalence is probably often underestimated and misinterpreted in clinical practice. This 
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especially applies to older patients who are more prone to ADRs due to frailty, reduced 
homeostasis, and multimorbidity and therefore constitutes a preventable cause of 
morbidity and mortality in the older population (Mallet et al. 2007). In PhaSiNAg, we 
investigated the concurrent use of potentially interacting drugs for selected antipsychotics 
according to the Flockhart list (Flockhart 2011). For instance, nearly two third of 
haloperidol users received concurrent treatment with a CYP2D6 inhibitor (data not shown 
in research article) leading to a possible diminished metabolism and increased plasma 
concentration of haloperidol. In a Swedish study by Johnell and Klarin (2007), the 
prevalence of potentially clinically relevant drug-drug interactions was 26% in the study 
population aged 75 years and older receiving at least two drugs concomitantly. The 
prevalence of potentially serious drug-drug interactions was five percent and strongly 
associated with the overall number of drugs used. Another study from Canada (Juurlink et 
al. 2003) investigated whether older patients admitted to the hospital with specific drug 
toxicities were more likely to have received an interacting drug in the week prior to 
admission. For instance, patients hospitalized due to digoxin toxicity were 12 times more 
likely to have been treated with the interacting antibiotic clarithromycin. Patients treated 
with ACE-inhibitors who were hospitalized due to hyperkalemia were even 20 times more 
likely to have been prescribed a potassium-sparing diuretic (Juurlink et al. 2003).  
In summary, multimorbidity constitutes a major problem in drug therapy of older patients. 
In the cases of polypharmacy and of several involved prescribing physicians, ADRs due to 
drug-drug interactions are likely and a preventable cause of morbidity and mortality in the 
older population.  
3.3.3. Potentially Inappropriate Medication in Older Patients  
In the last two decades, many activities were undertaken to improve the quality of 
prescribing in older patients by defining lists of potentially inappropriate medications 
(Gallagher et al. 2008, Laroche et al. 2007, McLeod et al. 1997, Rognstad et al. 2009). 
The most famous list is the Beers Criteria for determining potentially inappropriate 
medication in older patients which was first developed for licensed drugs in the United 
States and has been updated regularly (Beers 1997, Fick et al. 2003, American Geriatrics 
Society Beers Criteria Update Expert Panel 2012, American Geriatrics Society Beers 
Criteria Update Expert Panel 2015). For Germany, potentially inappropriate medication 
was defined for the first time in the PRISCUS list in 2010 in which 83 drugs from 18 drug 
classes were classified as inadequate for the use in older patients based on expert 
consensus (Holt et al. 2010). This list includes drugs possibly associated with a higher risk 
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of ADRs due to their pharmacological properties as well as recommendations for possible 
treatment alternatives and actions to be taken if these drugs are still used in older patients 
(Holt et al. 2010). Just recently, the EU(7)-PIM list of potentially inappropriate medications 
was developed by consensus of experts from seven European countries (Renom-Guiteras 
et al. 2015). 
We assessed the status of potentially inadequate prescribing in older patients in Germany 
according to the PRISCUS list before its publication to evaluate its relevance and to 
establish a reference for following studies. Approximately 25% of the study population 
received at least one prescription of a potentially inadequate medication, and the 
prevalence increased with age. Nearly nine percent received even four and more different 
potentially inadequate medications within the same year (Amann et al. 2012). An analysis 
by Linder et al. (2014) based on data from one large SHI showed that the percentage of 
older patients with at least one prescription of a potentially inappropriate medication 
decreased from 21.7% to 19.9% between 2008 and 2012.  
Nevertheless, it has to be noted critically that the PRISCUS and most other lists defining 
potentially inappropriate medications remain superficial, since they do not account for 
important clinical characteristics such as concomitant use of other drugs, co-morbidity, 
and the disease severity of the indication. In this context, the Screening Tool of Older 
Persons’ Prescriptions (STOPP) and the Screening Tool to Alert to Right Treatment 
(START) have been developed and updated by Gallagher and colleagues to take into 
account more clinical information (Gallagher et al. 2008, O'Mahony et al. 2015). In studies 
from Ireland and Sweden, inappropriate prescribing according to the STOPP criteria has 
been associated with an increased risk of avoidable adverse drug events in older patients 
compared to those without such drug prescriptions (Hamilton et al. 2011, Hedna et al. 
2015). Unfortunately, not all clinical information for the application of the STOPP criteria, 
e.g., the severity of heart failure according to the “New York Heart Association (NYHA) 
Functional Classification,” is available in detail in administrative claims databases like 
GePaRD. Therefore, their applicability in this setting is limited. 
4. Objectives 
Against this background, the evaluation of drug safety after marketing approval is of high 
public health interest. In this context, the subpopulation of older people receiving drug 
therapy is at particular risk of ADRs and will become more important in the future. Since 
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PSS in older patients based on spontaneous reporting systems and electronic healthcare 
databases face specific challenges, the objectives of this thesis are  
1. To critically assess methodological challenges of PSS after marketing approval 
based on spontaneous reporting systems and electronic healthcare databases 
with a focus on older patients and 
2. To define further areas of research to enhance the quality of PSS in older patients. 
Basic pharmacoepidemiological study designs and some important methodological 
challenges of PSS will be introduced and discussed in the next sections. This discussion 
also includes a critical post-hoc evaluation of the research articles and outlines possible 
improvements of my research. 
5. Methods for Drug Safety Studies 
5.1. Study Designs  
In the following, the basic study designs applied in the PSS described in this thesis are 
introduced (Schmedt et al. 2012, Schmedt and Garbe 2013a, Schmedt et al. 2016b). In 
general, pharmacoepidemiology applies classic epidemiological study designs, i.e., the 
(nested) case-control study and the cohort study with some specific adaptations mainly 
motivated by the nature of the exposure and electronic healthcare databases as primary 
data source (Schneeweiss and Avorn 2005). Although studies based on spontaneous 
reports cannot be interpreted in the same way as observational studies, the analysis 
strategy of a disproportionality analysis is similar to a case-control or cohort study. 
Besides classic epidemiological studies, case-only designs developed for specific drug-
safety-specific research questions are described. 
5.1.1. Disproportionality Analyses 
Spontaneous reporting systems only include case reports of possible ADRs submitted to 
the responsible authority. Since not all suspected cases of ADRs are reported and no 
information on the overall number of drug users is available, it is not possible to calculate 
incidence rates or risks based on this data. However, it is possible to check whether the 
proportion of reports of a specific ADR is higher among all reports of a specific drug 
compared to the reports of all other drugs (disproportionality analysis). The underlying 
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assumption is that an unexpected high reporting of a specific drug-ADR combination 
might point to a possible risk of the ADR for this drug (Garbe and Suissa 2014).  
As statistical measures of disproportionality, the proportional reporting ratio (PRR) and the 
reporting odds ratio (ROR) are frequently used (Bate and Evans 2009). These can easily 
be calculated based on a basic two-by-two table (Table 2).  
Table 2 Calculation of the proportional reporting ratio (PRR) and the reporting odds ratio 
(ROR) in spontaneous reporting systems 
Event of interest All other reported events
Drug of interest a b 
All other reported drugs c d 
Note: a,b,c and d are absolute frequencies 
The PRR is calculated as a/(a+b) divided by c/(c+d) and the ROR is calculated as a*d/b*c. 
In most cases, both measures are computed in conjunction with the respective chi-square 
value. A higher PRR or ROR indicates that the drug-ADR combination was reported more 
frequently than expected based on all other reports, i.e., the higher the PRR/ROR, the 
stronger the disproportionate reporting. An advantage of the ROR compared to the PRR is 
that multivariable logistic regression with additional adjustment for possible confounders 
as, for instance, age and sex can be used for its calculation. Besides the PRR and the 
ROR, more complex methods based on Bayesian statistics such as the Empirical Bayes 
Geometric Mean and the Information Component have been developed. These 
approaches are particularly useful to decrease the number of false positive signals if many 
drug-ADR combinations with a low observed number of events are investigated (Bate and 
Evans 2009). As threshold for a signal, Evans et al. (2001) proposed a PRR =>2, a chi-
square value of at least four, and a minimum of three exposed events of interest with the 
respective drug of interest.  
Once a signal for a possible drug-ADR combination has emerged, it has to be further 
evaluated based on a detailed review of case reports or PSS of higher quality, e.g., in 
observational studies based on electronic healthcare databases (Garbe and Suissa 2014).  
5.1.2.  Cohort Studies 
Many PSS based on electronic healthcare databases are conducted as retrospective 
cohort studies. In comparison to cohort studies in classic epidemiology, they differ 
predominantly with regard to the cohort entry which may be defined as date in time, 
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occurrence of specific a diagnosis or event or prescription of a drug (Garbe and Suissa 
2014). While cohorts beginning at a specific calendar date are rare, cohort entry at 
diagnosis or drug prescription is more frequent. An important problem of 
pharmacoepidemiological cohort studies based on electronic healthcare databases is left 
truncation of the data which impedes obtaining the complete history of previous diseases 
and medications. For event-based cohorts, bias can be introduced if the duration or 
severity of the disease event leading to cohort entry and exposure are both associated 
with the outcome under study (Garbe and Suissa 2014). For prescription-based cohorts, 
bias can arise in PSS if only prevalent users of the drug are included and patients with 
ADRs at an early stage of treatment are not considered after discontinuation of treatment 
(“depletion of susceptibles”) (Moride and Abenhaim 1994). Another problem of cohort 
studies is that the performance of the analysis and the interpretation may become very 
complex as soon as the exposure status changes during follow-up and exposure has to 
be assessed time-dependently. However, this may be necessary, since time-fixed 
analyses can introduce severe biases (immortal time bias, see section 5.2.4) or biased 
results through contamination of the exposure groups. 
5.1.3.  Nested Case-Control Studies 
The nested case-control study also constitutes a frequently used design in 
pharmacoepidemiological research based on electronic healthcare databases and actually 
reflects an analysis strategy within a previously defined cohort. The entry of such a cohort 
can be defined as a date in time, a specific age, the date of a specific diagnosis or the 
prescription of a drug. The cohort exit is usually defined as the end of the study period, 
death, the occurrence of the outcome or loss-to-follow-up, e.g., due to ending insurance 
membership (Garbe and Suissa 2014).  
Conducting a nested case-control analysis basically entails four steps. First, the time axis 
for the cohort has to be defined which can be calendar time or follow-up time. Second, all 
cases with the outcome event have to be identified and selected at the first occurrence 
during follow-up. Third, the risk set of possible controls has to be determined for each 
case. It consists of all individuals in the cohort at risk for the outcome at the date of the 
outcome occurrence of the respective case (index date). Last, a predefined number of 
controls has to be selected out of the risk set of each case (risk-set sampling). By 
definition, the control and the case have the same the index date (Essebag et al. 2003). In 
this context, the controls have to be considered as control person moments in time, i.e., 
every individual who served as a control can become a case later during follow-up. An 
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alternative approach to sampling controls from the risk-set at the index date is the random 
assignment of a person moment at risk for the outcome from the cohort as a control. 
Cases and controls are mostly matched by parameters such as age and sex, and 
statistical analysis is performed using conditional logistic regression. If the distribution of 
the exposure during person time of the controls is representative for the whole cohort, the 
obtained odds ratio can be interpreted as an efficient estimator of the rate ratio for both 
sampling approaches described above (incidence density sampling) (Garbe and Suissa 
2014, Rothman et al. 2008a).  
One major advantage of the nested case-control analysis based on electronic healthcare 
databases is that it can be performed more efficiently compared to the full cohort analysis 
with time-depending exposures. While the risk-set of each case consists of all controls at 
the index date using cox regression in the full cohort analysis, the nested case-control 
approach only requires a random sample of it (Garbe and Suissa 2014).  
5.1.4. Case-Only Designs  
Besides nested case-control and cohort studies, case-only designs are frequently used to 
overcome certain difficulties of pharmacoepidemiological studies. As described below, 
confounding by indication or unmeasured confounding might be a serious problem if both 
the underlying indication or its severity and the drug exposure are associated with the 
outcome or if important confounders cannot be assessed in electronic healthcare 
databases. Under these circumstances, case-only designs may serve as alternatives if the 
key assumptions of the respective study design are fulfilled (Garbe and Suissa 2014). In 
the following, the case-crossover and the self-controlled case series design as case-only 
designs predominantly used in pharmacoepidemiology are introduced in more detail. 
5.1.4.1. Case-Crossover Design 
The case-crossover design can be considered a case-control study in which cases serve 
as their own controls. For each case, exposure status within a predefined risk period prior 
to the event and within one or more control periods is assessed. The statistical analysis is 
performed as conditional logistic regression taking into account the matched nature of the 
data. In order to apply this design, three requirements have to be fulfilled. First, the 
outcome under study must be an acute ADR resulting from a transient drug effect. 
Possible ADRs with a long induction period and drugs used continuously over a long time 
period, e.g., antihypertensive or antidiabetic medication, are difficult to investigate based 
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on this design. Second, the time window of the drug effect has to be defined exactly as 
the period under risk of the ADR. Third, data for a sufficiently long time period have to be 
available for each case to assess information on the exposure prior to the event assuming 
that the probability of drug exposure has not changed over time (Maclure 1991). If the 
latter is not the case, the case-time-control design proposed by Suissa (1995) can be 
used as an extension of the case-crossover design to account for time-trend biases.  
5.1.4.2. Self-Controlled Case Series Design 
The self-controlled case series design was developed by Farrington (Farrington 1995). At 
the beginning, it was primarily used to study acute ADRs of vaccinations, but later it was 
also applied to investigate other drug exposures and non-acute outcomes, e.g., autism. 
Similar to the case-crossover design, it can be used to analyze possible ADRs of transient 
exposures considering only individuals who developed the outcome of interest. However, 
it rather conveys the idea of a cohort study and several events per individual can 
contribute to the analysis which is not possible in the case-crossover design (Garbe and 
Suissa 2014).  
Basically, the self-controlled case series method is used to estimate the relative incidence 
of the possible ADR or outcome of interest during a predefined risk period after drug 
exposure (risk period) compared to the remaining time of the individual during follow-up as 
control period. At first, the study time window is defined which can be a specific age-range 
or calendar time period. Afterwards, all individuals who experienced the outcome of 
interest are selected and the follow-up time during the study time window is determined. 
Then, drug exposure is assessed for all cases and the risk period has to be defined 
depending on the pharmacological properties of the respective study drug and 
mechanisms leading to the outcome event. Thus, the whole observation period for each 
case can be subdivided into periods at risk and control periods and the date of the 
outcome events can be assigned to one of these periods. The relative incidence of the 
outcome between risk periods and control periods is then modeled using conditional 
Poisson regression (Garbe and Suissa 2014, Whitaker et al. 2006).  
In general, three key assumptions have to be met in the basic approach. First, the 
occurrence of the outcome has to be the result of a non-homogeneous Poisson process. 
Second, the occurrence of an outcome must not affect the probability of drug exposure 
and, third, the outcome event must not censor or influence the observation period of an 
individual otherwise (Whitaker et al. 2009). For this reason, death and severe events 
leading to death shortly after their occurrence should not be investigated according to the 
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basic approach; however, extended methods have been developed to study such events 
(Whitaker et al. 2006).  
5.2.  Methodological Challenges in Drug Safety Studies 
In this section, selected methodological challenges of PSS based on electronic healthcare 
databases are introduced. The selection of topics was based on aspects that had to be 
addressed in the research articles included in this thesis. The main limitations of 
disproportionality analyses refer to the quality and reporting of spontaneous reports and to 
a lesser extent to methodological aspects. Therefore, these limitations are not presented 
in this section as methodological aspects, but highlighted and discussed later in section 
6.1. However, some challenges described hereafter can also affect studies based on 
spontaneous reporting systems, e.g., confounding as well as outcome and exposure 
misclassification. 
5.2.1. Unmeasured Confounding, Confounding by Indication and 
Channeling Bias 
As in all non-randomized observational research, one of the most important challenges in 
PSS after marketing approval is confounding bias (Schneeweiss and Avorn 2005). As 
described above, many administrative claims databases as GePaRD miss detailed 
information on important possible confounders, e.g., body weight, history of smoking, 
alcohol consumption, and other lifestyle-related factors such as physical activity (see 
section 3.2.2). If these factors are associated with both outcome and exposure status, 
unmeasured and residual confounding may lead to biased risk estimates and as a 
consequence to the misinterpretation of study results. 
A general concern in pharmacoepidemiological studies after marketing approval is 
confounding by indication. If drug use is compared to non-use, it occurs if the indication 
for the drug itself is a risk factor for the outcome under study (Schneeweiss and Avorn 
2005). In comparative effectiveness and safety studies, confounding by indication often 
appears if the drug under study and the comparator drug are indicated in patients at 
different stages of the treated disease (confounding by disease severity). If the disease 
severity is associated with the outcome, the drug used in those most severely affected by 
the illness will be disadvantaged by confounding (Garbe and Suissa 2014, Walker 1996). 
Of note, confounding by indication more often affects studies that investigate the intended 
effects of drugs because the indication for drug use is usually associated with the 
outcome by definition. In contrast, it is less common in studies investigating ADRs, since 
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these are usually unintended and not associated with the indication of the drug (Strom 
and Melmon 2012). For instance, confounding by indication will be a problem if the risk of 
myocardial infarction in statin users is compared to non-users, but not if the outcome 
under study is rhabdomyolysis. The reason behind this is that statins are indicated for 
hypercholesterolemia and for secondary prevention of cardiovascular events, both of 
which strong risk factors for myocardial infarction, but not for the unintended ADR 
rhabdomyolysis.  
Even if the drugs compared with regard to a specific outcome are used for the same 
indication, drug prescribing by physicians in routine care may be influenced by patient 
characteristics leading to confounding by drug channeling to patients at high risk for the 
outcome (channeling bias) (Schneeweiss and Avorn 2005). For example, MacDonald et 
al. (2003) showed that meloxicam and cyclooxygenase-2 inhibitors as newer class of non-
steroidal-anti-inflammatory drugs were predominantly prescribed to patients at very high 
risk for gastrointestinal bleeding in clinical practice because they were supposed to have 
gastro-protective effects compared to classic NSAIDs. This prescribing pattern probably 
led to the wrong conclusion in other studies that the use of these newer NSAIDs is not 
associated with a beneficial effect with regard to the risk of gastrointestinal bleeding 
(MacDonald et al. 2003). Another example is the higher risk of falls and hip fractures 
observed for newer benzodiazepines compared to older agents. In this case, newer 
agents were preferentially prescribed to frail older patients who are at higher risk for such 
ADRs resulting in unmeasured confounding and an overestimation of the risk of fall and 
hip fractures compared to older agents (Schneeweiss and Wang 2005).  
In PSS among older patients, confounding by frailty is often a problem. Frailty is defined 
as higher vulnerability to stressors resulting from decreased physiological reserves in 
multiple systems characterized by nutritional decline, fatigue, decreased activity, and 
overall weakness leading to a higher risk of adverse health outcomes including mortality 
and a lower probability to receive preventive treatments (Fried et al. 2004). As the concept 
has to be distinguished from co-morbidity (Fried et al. 2004), frailty is very difficult to 
measure based on electronic healthcare databases (Glynn et al. 2001).  
5.2.2. Outcome Misclassification 
An important prerequisite to conduct high quality PSS is the accurate assessment of the 
study outcomes. For the evaluation of the accuracy of an outcome based on 
administrative claims data, the first important aspect is to know how the data were created 
and processed and for which purposes they were collected (Lanes et al. 2015). For 
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instance, hospital diagnoses are typically used for reimbursement based on DRGs. 
Therefore, hospitals have a high interest in correctly coding diseases, especially for 
severe cases (Schneeweiss and Avorn 2005). In addition, the quality of hospital 
diagnoses is often routinely checked by health insurance providers as they pay for 
hospital care of their insurance members. In contrast, ambulatory diagnoses typically do 
not affect reimbursement and are therefore subject to less quality checks (Lanes et al. 
2015). If the diagnostic certainty is not adequately captured by physicians in the outpatient 
setting, bias can, for instance, be introduced by misclassification of suspected or ruled out 
diagnoses as ascertained diagnosis (Schneeweiss and Avorn 2005).  
In general, the possibility of identifying an outcome based on administrative claims data 
depends on the acuity and onset of the respective event. For instance, stroke or 
myocardial infarction typically occur rapidly and require immediate treatment in the 
hospital setting, i.e., the date of onset can be determined exactly in most cases. Thus, 
these acute and severe outcomes are well captured based on administrative claims data 
as shown in validation studies from the Unites States (Brouwer et al. 2015, 
Lakshminarayan et al. 2014). In contrast, chronic disease outcomes with potentially long 
latency periods not necessarily requiring hospitalization, e.g., heart failure or type 2 
diabetes, may be more difficult to investigate. Even if additional information on specific 
treatments (e.g., antidiabetic drugs) is used to define the onset date, the chronology of 
exposure and event may not be correctly assessed and protopathic bias might occur 
(Lanes et al. 2015).  
In addition, outcome misclassification in PSS can especially bias the effect estimate if the 
specificity of the recorded diagnoses is low. In case of 100% specificity of the diagnosis, 
relative risk estimates will remain nearly unbiased in the case of non-differential 
misclassification even with a low sensitivity in most cases (Rothman et al. 2008b, 
Schneeweiss and Avorn 2005). A major concern is therefore differential misclassification, 
e.g., if an outcome is expected under treatment with a specific drug and these patients are 
more closely monitored compared to the unexposed group (detection bias).  
5.2.3. Exposure Misclassification 
Besides the adequate assessment of outcome events, it is crucial in PSS based on 
electronic healthcare databases to ascertain the exposure of drugs appropriately.  
For instance, many ADRs occur during the first days of drug treatment. In this case, it is 
essential to have valid exposure information to prevent misclassification of the exposure 
status. This applies for both cohort studies and nested case-control studies in which drug 
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exposure has to be captured on a daily basis to define exposure risk windows (Garbe and 
Suissa 2014). Administrative claims data are often considered the gold standard for the 
assessment of drug exposure information, since prescriptions usually have to be filled in 
the pharmacy to get reimbursed by health insurance providers (Schneeweiss and Avorn 
2005); however, some challenges to define the exact exposure status for patients remain. 
Misclassification may occur in administrative claims data because the exact duration and 
dose of drug treatment are typically not documented. While medical record databases 
often contain information on the prescribed daily dose or the amount of tablets etc. to be 
taken, pharmacy dispensing information usually does not provide this information, and the 
duration of therapy and dose have to be estimated based on assumptions on the regular 
drug intake of the patient, e.g., based on the prescribed amount of DDDs or by assigning 
a fixed supply for each prescription (Garbe and Suissa 2014, Schneeweiss and Avorn 
2005). Under these assumptions, misclassification can mainly occur in two different ways. 
First, patients can be falsely considered as unexposed if they take the respective 
medication at a lower dosage or “as-needed” which might be a specific problem in older 
patients (see section 3.3.2). Second, patients might be misclassified as exposed if they 
filled the prescription, but decided to stop the drug for reasons like side effects or 
perceived missing efficacy (Schneeweiss and Avorn 2005). Furthermore, overlapping 
prescriptions may introduce exposure misclassification because it is not clear whether the 
patient used the drug at a higher dosage or the prescription was filled and the drug used 
later. Depending on the medication, it has to be decided if the supply of the previous 
prescriptions is concatenated or the supply of the following prescriptions is added to the 
previous one (stockpiling) (Greevy et al. 2011). 
5.2.4. Time-Related Biases 
The most important time-related biases in pharmacoepidemiological studies are immortal 
time and time-window bias. Immortal time bias typically occurs if a time-fixed analysis is 
used in cohort studies to emulate an intention-to-treat approach of an RCT (Suissa 2007). 
In this case, immortal time refers to a time period during follow-up, in which the outcome 
under study could not have occurred due to the definition of exposure assessment. In 
many studies, this time period refers to cohort time prior to initiating a specific drug 
treatment during which the patient had to stay event free until being classified as exposed. 
If this period is incorrectly considered as exposed (information bias) or alternatively 
disregarded in the analysis (selection bias), this leads to immortal time bias (Levesque et 
al. 2010, Suissa 2008b).  
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studies, and their advantages and disadvantages are pointed out. In addition, the first part 
of this section contains a discussion of the role of disproportionality analyses based on 
spontaneous reports for drug safety evaluations after marketing approval.  
6.1. Disproportionality Analyses Based on Spontaneous Reporting 
Systems – A First Step 
Disproportionality analyses based on spontaneous reporting systems have to be 
considered an important tool to evaluate drug safety after marketing approval. The main 
advantage of disproportionality analyses and spontaneous reporting systems is that case 
reports are immediately available for assessment upon submission. In many electronic 
healthcare databases, data delivery is often delayed, i.e., drug safety evaluations cannot 
be conducted until 1.5 to 2 years after marketing approval. However, at this time, many 
patients may already have experienced serious ADRs. In addition, disproportionality 
analyses are valuable to study rare ADRs mostly related to drug use. For instance, we 
studied safety signals of PML in users of selected immunosuppressants (Schmedt et al. 
2012). PML was suitable for a disproportionality analysis because it is very rare and most 
cases - except in patients with HIV/AIDS - are related to immunosuppressive drug 
treatment (Weber 2008). Besides, as PML is uncommon it would probably not be possible 
to conduct a PSS with sufficient statistical power based on large electronic healthcare 
databases such as GePaRD. 
On the other hand, disproportionality analyses based on spontaneous reporting systems 
have inherent limitations. Therefore, they can only serve as a first step to generate 
hypotheses about possible ADRs and cannot replace PSS on more accurate data (Garbe 
and Suissa 2014).  
The first limitation of disproportionality analyses refers to the data quality of case reports 
in spontaneous reporting systems. Based on our studies (Andersohn et al. 2010, Schmedt 
et al. 2012), important information such as on age and sex is often missing. A recent study 
showed that case reports submitted to the U.S. Food and Drug Administration by drug 
manufacturers in 2014 contained complete information on age, sex, event date, and the 
medical term of the ADR in only 41%. Age was missing in 38% (Moore et al. 2016). In this 
case, it is difficult to investigate age effects and disproportionate reporting in specific age 
groups such as older patients. In addition, follow-up reports of the same suspected ADRs 
are often not adequately recorded in the spontaneous reporting system. In our study 
investigating the association between immunosuppressants and PML (Schmedt et al. 
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2012), we excluded 84 duplicates out of 719 reports of PML from the analysis after 
manual review. For several case reports, more than five duplicates were identified. If 
these cases had not been excluded, this would have led to substantial bias in the 
calculation of the ROR in our study. 
The second important limitation of disproportionality analyses is selective reporting of 
specific drug-ADR combinations (reporting bias) (Moore et al. 2003). The correct 
interpretation of the ROR and PRR actually requires that the underreporting of ADRs is 
similar for the drug of interest and all other drugs in the comparison group, and that it is 
stable over time. However, it has been shown that increased medical and media attention 
for a specific drug-ADR combination can lead to selective reporting (Griffin 1986) and that 
public safety warnings can stimulate the reporting of ADRs for a specific drug (notoriety 
bias) (Pariente et al. 2007). In general, reporting rates typically change over time. The 
Weber effect was first described in the 1980s and replicated in later studies (Hartnell and 
Wilson 2004). It depicts the phenomenon that ADR reporting continuously rises within the 
first 18 to 24 months after marketing approval and then steadily decreases despite a 
growing market share (Weber 1984). Although other analyses did not reveal the typical 
pattern for the Weber effect, reporting of ADRs in those studies was also not stable over 
time for most drugs (Hoffman et al. 2014, Wallenstein and Fife 2001). As a result, 
selective reporting can lead to false-positive signals of specific ADR-drug combinations, 
but it can also mask signals of the same ADR for other drugs (competition bias) (Pariente 
et al. 2012a). For example, in our study on PML (Schmedt et al. 2012) it is likely that the 
ROR was overestimated for some drugs that had gained particular media attention due to 
a possibly higher risk, e.g., natalizumab which had been withdrawn for 16 months due to 
case reports of PML. On the other hand, higher reporting of PML cases associated with 
natalizumab could have obscured the detection of signals for other immunosuppressants 
The third limitation of disproportionality analyses is the fact that they are less suitable for 
specific safety outcomes; this particularly applies to older patients. ADRs occurring a long 
time after drug treatment (“type D reactions”) may often not be reported, since they are 
not considered related to a drug intake from many years before. The same applies to 
ADRs with a high background incidence in the population. For example, possible life-
threatening ADRs such as ischemic stroke or myocardial infarction are difficult to analyze 
because they frequently occur among older patients and may thus not be considered 
possible ADRs. In this context, it has to be assumed that many serious ADRs are 
underreported in the subgroup of older patients. 
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6.2. Confounding in Drug Safety Studies – Big Problems, Promising 
Approaches 
Confounding bias can be addressed in several ways in PSS. For measured confounders, 
restriction or matching can be applied at the stage of the study design and 
standardization, stratification or adjustment in multivariable regression can be used in the 
analysis. For unmeasured confounding, case-only designs and advanced methods as the 
high-dimensional propensity score (HDPS) can be used. The application and usefulness 
of these methods are discussed in the following section based on my research with a 
focus on older patients. Further approaches to address unmeasured confounding in PSS 
are, for instance, the application of instrumental variables or two-stage sampling 
(Schneeweiss 2006); however these methods are not discussed here. 
6.2.1. Drug Utilization Studies to Detect Possible Confounding 
and Channeling 
The first step to mitigate confounding in PSS is to carefully define and assess possible 
confounders available in the electronic healthcare database, i.e., all diseases, drug 
treatments etc. that may be independently associated with the study endpoint.  
Before we compared the risk of death between different antipsychotics and risperidone in 
older patients (Schmedt et al. 2016b), we conducted a detailed drug utilization study to 
assess the baseline prevalence of important possible confounders and indications 
(Schmedt et al. 2016a). This was particularly important in the analysis of older patients, in 
whom antipsychotics are used for various indications, e.g., dementia, sleeping disorders, 
depression, etc. For instance, we found that users of haloperidol more frequently had a 
diagnosis of metastatic solid tumors than patients treated with other antipsychotics 
(Schmedt et al. 2016a), since it is also used as an anti-emetic and sedative in palliative 
care (McLean et al. 2013). Consequently, a strong association with haloperidol and the 
outcome death was expected. This would have resulted in strong confounding and an 
overestimation of the increased risk of death for haloperidol compared to other 
antipsychotics. To avoid this bias, we excluded patients with any cancer diagnosis, 
antineoplastic treatment or other records indicative of palliative care prior to cohort entry 
from the safety analysis (Schmedt et al. 2016b).  
Another finding to highlight the importance of detailed drug utilization studies as a 
prerequisite for a comparative safety study is the example of the long acting antipsychotic 
fluspirilene. It is currently only indicated for the treatment of schizophrenia, but older 
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studies suggested that fluspirilene may also be used as an alternative to or add-on for 
benzodiazepine tranquilizers in older patients (Schmidt 1989). Our drug utilization study 
revealed that patients treated with fluspirilene had less diagnosed somatic and psychiatric 
co-morbidity and that the drug was more often used in mild psychiatric conditions 
compared to other antipsychotics (Schmedt et al. 2016a). We finally refrained from 
analyzing fluspirilene in the safety analysis because of suspected biased results through 
strong unmeasured confounding (Schmedt et al. 2016b).  
6.2.2. High-Dimensional Propensity Score 
The HDPS has been proposed by Schneeweiss et al. (2009) as an extension of the 
traditional propensity score (PS) method. The PS is calculated with logistic regression 
modeling the probability of receiving a drug compared to another drug or no treatment 
depending on a pre-defined set of confounding variables (Sturmer et al. 2014). In contrast, 
the HDPS is additionally calculated incorporating a set of many empirically selected 
confounding variables (often up to 500). The calculation of the HDPS basically includes 
the following five steps: (i) identification of the data dimensions, e.g., inpatient and 
outpatient diagnoses, inpatient operations and procedures, outpatient diagnostic and 
therapeutic procedures, and outpatient dispensations, (ii) selection of candidate codes 
based on their prevalence, (iii) construction of covariates based on the recurrence of the 
respective codes, (iv) prioritization of the covariates based on the estimated strength of 
confounding according to the Bross formula within each data dimension, and (v) selection 
of the covariates with the strongest confounding and calculation of the HDPS 
(Schneeweiss et al. 2009). As with traditional PS analyses, a comprehensive diagnostic of 
the HDPS analysis must be performed which may involve the use of HDPS in several 
ways, e.g., stratification, adjustment, inverse probability of treatment weighting, and 
matching in combination with or without different trimming approaches (Sturmer et al. 
2014). The correct implementation and the appropriateness of the HDPS analysis always 
depend on the research question and the population under study.  
In our comparative safety study on antipsychotics and death in older patients, we used the 
HDPS as matching parameter and adjusted for HDPS-deciles in the Cox-proportional 
hazards model to account for possible unmeasured confounding in the conventional 
multivariable regression analysis. Although no substantial differences were observed, the 
hazard ratio for some comparisons in the HDPS analysis tended towards a null effect in 
the HDPS adjusted and matched analysis which may indicate remaining unmeasured or 
residual confounding (Schmedt et al. 2016b). The HDPS has to be considered particularly 
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useful in our study among the heterogeneous group of older patients in whom the drugs 
under study were used for various indications and therefore strong confounding must be 
assumed. In this case, the HDPS approach might facilitate the empirical selection of 
proxies for unmeasured confounders, e.g., frailty, for which there is no established score 
or index based on administrative claims data (Kim and Schneeweiss 2014). In future 
studies, the performance of the HDPS in older patients would benefit if data on nursing 
care and remedies could be used as additional data dimension. Probably, these include 
important additional proxies on possible unmeasured confounders. Unfortunately, these 
data were not available in our study (Schmedt et al. 2016b).  
6.2.3. Application of case-only designs 
In general, case-only designs can be considered valuable tools to investigate possible 
acute ADRs for transient drug exposures because of their ability to inherently control for 
time-invariant confounders that cannot be assessed in electronic healthcare databases. 
This is especially advantageous in PSS among older patients whose individual 
constitution and response to drugs may differ substantially (see section 3.3). In addition, 
many drugs are not used over longer periods in older patients. For instance, 
antipsychotics are often used “as-needed” in patients with dementia and for a short 
duration (Schmedt et al. 2016a). For acute ADRs assumed to occur under current 
treatment of antipsychotics, e.g., ischemic stroke, myocardial infarction, ventricular 
arrhythmia (Trifiro et al. 2014), a case-only design can therefore be considered an equal 
or even preferable study design compared to a classic cohort or nested-case control 
study. Consequently, the risk of myocardial infarction and stroke associated with 
antipsychotic use was recently evaluated based on case-only designs in the whole 
population (Brauer et al. 2015, Lin et al. 2014) and more specifically among older patients 
(Pariente et al. 2012b, Shin et al. 2013). Retrospectively, a case-only design would also 
have been an interesting additional approach to study the risk of VTE under antipsychotic 
treatment in patients with dementia complementing our nested-case control study 
(Schmedt and Garbe 2013a). 
On the other hand, case-only designs are often not suitable for relevant drug safety 
questions. For instance, it is nearly impossible to study long-term safety outcomes such 
as cancer, and it is also not possible to evaluate safety concerns of drugs continuously 
used over long time periods. In addition, it is only possible to control for time-invariant 
unmeasured confounders; however, many possible confounders vary with time in the 
same individual in clinical practice (Hallas and Pottegard 2014). For instance, in our self-
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controlled case series analysis on stimulant use and the risk of injuries in children with 
attention deficit/hyperactivity disorder, a major concern was that the severity of symptoms 
may vary over time and trigger prescriptions of methylphenidate or atomoxetine 
(Mikolajczyk et al. 2015). We did not consider this as a problem because such 
confounding by disease severity would have diluted a possible beneficial effect that was 
still observed; however, in a PSS this could lead to an overestimation of drug risks. 
Another problem that may particularly limit the applicability of case-only studies is 
exposure misclassification in older patients. Although this also applies to all other study 
designs, the correct assessment of the exposure risk window is particularly important in 
case-only studies in which usually transient drug effects are measured (Hallas and 
Pottegard 2014). Unfortunately, the assessment of transient drug exposure is extremely 
challenging if the duration of use has to be estimated, and exposure misclassification is 
more likely in older patients due to larger variations of doses, lower adherence, up-
titration, and tapering etc. For a more detailed discussion of exposure misclassification, 
see section 6.4. 
6.3. Avoiding Outcome Misclassification – We Can Do Better! 
Outcome misclassification is often neglected in PSS based on administrative claims data, 
although it can be addressed in several ways. 
To assess the accuracy of a case-algorithm, it should ideally be validated against a well-
suited gold standard, e.g., medical records or physician questionnaires. If this is not 
possible, alternative strategies for validation may be used as, for instance, the comparison 
of event rates against reliable data from other sources (Lanes et al. 2015, Schneeweiss 
and Avorn 2005). As an example, we compared the age- and sex-standardized mortality 
rates in GePaRD to those from the German Federal Statistical Office. Although we found 
discrepancies that may be related to differences with regard to the socioeconomic status 
of the study populations, the results led to the conclusion that death is reliably recorded in 
GePaRD (Ohlmeier et al. 2015). In a similar approach, we compared the event rates of 
several study outcomes, e.g., stroke, acute myocardial infarction, pancreatic cancer, etc., 
in the EU-funded multi-database study “Safety Evaluation of Adverse Reactions in 
Diabetes” (SAFEGUARD) across different data sources and with event rates reported in 
the literature (Schmedt et al. 2013). However, there are two major limitations of this 
approach: (i) even if the event rates are similar across data sources, it is possible that 
false-positive events mask false-negatives, and (ii) the results of this approach cannot be 
transferred to a specific study population, e.g., a cohort of older patients with dementia. 
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If external validation cannot be performed at all, other strategies to enhance the specificity 
of a case-algorithm should be considered. In GePaRD, the main hospital discharge 
diagnosis is often used for acute and severe events and diagnoses from the outpatient 
setting are usually not taken into account. We also used this approach in our nested-case 
control study on the risk of VTE in older users of antipsychotics (Schmedt and Garbe 
2013a). In most cases, the specificity of the case-algorithm may be further increased by 
using additional information on drug treatment of the outcome or obligatory diagnostic 
tests (The European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance 2015). For instance, a case-algorithm for VTE could have included 
additional information on the use of anticoagulants or possible records for an ultrasound. 
Although this is rarely done, a detailed review of the patient’s profile based on the 
available information in administrative claims data can also be performed. Two 
experienced reviewers can evaluate all possible cases, and implausible events can be 
excluded to increase the specificity of the case algorithm. A manual review might be 
considered particularly important in older patients because there are usually more 
differential diagnoses, and less diagnostic tests may be performed which can decrease 
the specificity of using diagnoses alone. In the case of many outcomes for manual review, 
diagnostic tests or information on drug treatment can also be implemented in automated 
case-algorithms.  
In order to detect possible differential misclassification of the outcome case-algorithm 
(detection bias), it can be useful to count the number of performed diagnostic tests for the 
outcome for all exposure groups. For instance, the number of liver tests can be counted if 
the outcome under study is acute liver injury. This approach can be particularly important 
if the occurrence of a specific ADR is already suspected for a specific drug, and treated 
patients are more closely monitored. 
6.4. Assessing Drug Exposure in Administrative Claims Data – A 
“Double-Edged Sword” 
On the one hand, the assessment of drug exposure in older patients based on 
administrative claims data has many advantages and is often considered the gold 
standard in PSS as recall bias can be ruled out and prescribing information is also 
available for subpopulations that are difficult to recruit for field studies, e.g., older patients 
suffering from severe disease such as dementia (Schneeweiss and Avorn 2005) (see also 
section 3.2.2). For instance, in GePaRD, more detailed information is available via linkage 
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to a central pharmaceutical reference database, e.g., on the route of administration and 
the strength of the drug, which can provide a comprehensive picture of the respective 
drug exposure in older patients.  
On the other hand, exposure misclassification can occur in several ways because the 
duration of drug treatment has to be estimated because the exact prescribed dose is not 
available. For chronic treatment such as antidiabetic drugs or antihypertensives, the 
problem of misclassification is of less relevance, since continuous refills at least indicate 
regular treatment and gaps between prescriptions may be combined to continuous 
treatment episodes by adding pre-defined fractions to the estimated drug supply (e.g., 
seven days or 50% of the prescribed DDD) (Gardarsdottir et al. 2010, Schneeweiss and 
Avorn 2005). However, the correct assignment of the exposure status for drugs assumed 
to be rather used “as-needed” or for very short time periods is more challenging 
(Schneeweiss and Avorn 2005) because the actual duration of use between two 
prescriptions or for a single prescription remains unknown. In older patients, “as-needed” 
treatment frequently occurs, e.g., in treatment with nonsteroidal anti-inflammatory drugs or 
with antipsychotics in dementia. In our studies on antipsychotics (Schmedt et al. 2016a, 
Schmedt et al. 2016b), we added 150% of the prescribed DDD for each antipsychotic 
dispensation and then created episodes of continuous treatment as displayed in Figure 3.  
Figure 3 Construction of antipsychotic treatment episodes from Schmedt et al. 2016a 
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In the case of longer time periods between two prescriptions for the same patient (e.g., 
patient 2), it is unclear if the patient continuously used the drug at a low dose or 
sporadically at a higher dose. In this case, administrative claims data are still useful; 
however, an exposure misclassification cannot be ruled out and sensitivity analyses are 
crucial to assess the consistency of the results under different assumptions. This 
particularly applies to studies in which the timing of exposure has to be determined 
exactly, e.g., in case-only studies (see section 5.1.4). In our study, we performed 
sensitivity analyses adding 0%, 50%, 100%, 200%, and 300% of the prescribed DDD to 
assess the consistency of the treatment duration under different assumptions (Schmedt et 
al. 2016a). 
Besides, exposure misclassification may occur in administrative claims data if drug 
exposure in the hospital setting is not documented as is the case in GePaRD. If this 
misclassification is differential between exposure groups, this may lead to biased risk 
estimates, especially if the outcome under study is mortality (“immeasurable time bias”) 
(Suissa 2008a). Of course, this form of exposure misclassification is most relevant in older 
patients with severe co-morbidity who are hospitalized more often and for longer time 
periods, e.g., patients with dementia. Although this bias cannot be prevented, its possible 
impact and direction can be estimated by comparing the amount of hospitalized person 
time between the exposure groups. We did this in our comparative safety study on 
antipsychotics and death and found no substantial differences between the exposure 
groups (Schmedt et al. 2016b). In this context, it also needs to be emphasized that nested 
case-control studies, in which exposure status is often defined based on the last drug 
prescription before the index date, are more prone to this form of exposure 
misclassification. This was one of the reasons why we chose a cohort study with a 
modified intention-to-treat design in our study on the comparative risk of death in older 
antipsychotic users (Schmedt et al. 2016b).  
Finally, a general problem in PSS with regard to the exposure based on administrative 
claims data is the missing information on the prescribed dose. Again, for chronic 
treatments, the dose can be estimated based on the time between two prescriptions. In 
contrast, it cannot be determined if “as-needed” treatment is frequent. This was the case 
in our drug utilization study of antipsychotics in older patients in which 44% of new users 
had only one treatment episode, and the median treatment duration was only 20 days 
(data not shown in research articles). Therefore, we were not able to analyze dose effects 
in the following safety study (Schmedt et al. 2016b), although previous studies had 
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reported substantial dose effects regarding the risk of death under antipsychotic 
medication (Gerhard et al. 2014, Huybrechts et al. 2012).  
6.5. Time-Related Biases – Unnecessary Problems! 
Immortal time bias and time-window bias have been introduced as potential pitfalls that 
can affect cohort studies and case-control studies, respectively (see section 5.2.4). This is 
true for PSS among all age groups and is not restricted to older patients. Instead, it is 
important to emphasize that these forms of biases are always introduced by the choice of 
the study design and can easily be prevented (Suissa 2008b).  
As described above, immortal time bias is usually introduced through an inappropriate 
time-fixed analysis in which unexposed person time is wrongly considered as exposed 
person time (information bias) or unexposed person time before drug exposure is deleted 
entirely from the analysis (selection bias) (see section 5.2.4). This problem can be solved 
in most circumstances by using a time-dependent analysis (e.g., in the Cox proportional 
hazard model) (Suissa 2008b). In addition, it is important that treatment groups are not 
assigned hierarchically because exposure periods of drugs at a lower hierarchy level 
would thus be disregarded in the analysis. In the same manner, patients should not be 
excluded based on drug exposure assessed during follow-up (Levesque et al. 2010).  
Time-window bias is introduced in nested-case control studies if the length of the 
exposure time window is systematically different for cases and controls. This form of bias 
can be avoided by using incidence density sampling (Suissa et al. 2011). For instance, in 
our study on VTE in older users of antipsychotics with dementia, we used risk-set 
sampling to select controls and defined the exposure status based on antipsychotic 
prescriptions in the 365 days before the index date of the case. Since all persons in the 
cohort had a minimum look-back period of 365 days before cohort entry, the exposure 
time window of all cases and controls had the same length (Schmedt and Garbe 2013a). 
In studies without a fixed exposure time window (e.g., if exposure is defined as “ever use” 
of a drug), additional matching by duration of follow-up or the date of cohort entry between 
cases and controls can be performed to prevent time-window bias.  
7. Conclusions and Future Perspectives 
The post-marketing evaluation of drug safety in older patients including the prevention of 
ADRs is of enormous public health interest. In light of the ageing society and the 
corresponding increase of drug use, its importance will increase even more in the future. 
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In this context, this thesis demonstrated that spontaneous reporting systems and PSS 
based on electronic healthcare databases are essential to detect ADRs after marketing 
approval and to overcome limitations of RCTs. However, it also emphasized important 
problems with regard to the quality of spontaneous reports and electronic healthcare 
databases as well as methodological pitfalls of PSS. Since some of these are particularly 
relevant for PSS in older patients, these challenges have to be addressed in future 
research activities. 
More specifically, this thesis demonstrated that disproportionality analyses based on 
spontaneous reports are useful to analyze rare and specific ADRs such as PML; however, 
the method is generally hampered by the poor quality of the data. In addition, 
disproportionality analyses based on spontaneous reports are less suitable for the 
detection of ADRs in older patients if the background incidence of the ADR in the 
population is high. In this context, it has recently been shown that data mining approaches 
based on electronic healthcare databases have a greater potential to detect signals of 
more common ADRs (Patadia et al. 2015). As another example, sequential matched 
cohort studies have been applied as semi-automated active safety monitoring of newly 
marketed drugs based on electronic healthcare databases in the United States (Gagne et 
al. 2012). In addition, different approaches for signal detection have also been applied 
based on GePaRD (Suling and Pigeot 2012). Given the higher quality of data compared to 
spontaneous reports and the availability of established data sources like GePaRD, active 
semi-automated safety monitoring of new drugs based on electronic healthcare databases 
should be more often considered and further developed in Germany in the future. Of 
course, as a prerequisite, the data from SHIs would have to be delivered in a timelier 
manner to detect ADRs soon after marketing approval. 
Moreover, this thesis revealed that confounding bias is one of the most important potential 
pitfalls in non-randomized drug safety research. Although PSS based on electronic 
healthcare databases can be considered the preferred alternative to study the safety of 
drugs in older people, confounding was identified as a particular concern in this very 
heterogeneous and vulnerable subpopulation (e.g., confounding by frailty). In this context, 
this thesis showed that drug utilization studies are crucial to detect possible drug 
channeling and to explore the potential for confounding by indication prior to the safety 
study itself. Furthermore, the HDPS method was applied in a study on the comparative 
risk of death in older antipsychotic users and discussed as a new promising approach to 
address unmeasured confounding based on empirical selection of potential proxies for 
confounders not captured in electronic healthcare databases (e.g., frailty). In addition, 
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case-only designs have been introduced as an alternative study design to overcome 
unmeasured confounding in the case of transient drug treatments, e.g., with 
antipsychotics in older patients. Beyond these approaches, the increasing digitalization 
may offer additional opportunities in the future if confounder information available in 
electronic healthcare databases can be enriched through linkage with other data sources. 
These could, for instance, include data from large field studies or information on physical 
activity from electronic tracking devices. In particular for Germany, the recent passage of 
the “e-health” legislation and the introduction of the electronic health card could imply 
further alternatives since more detailed clinical information such as laboratory test results, 
more detailed information on drug treatment and images from x-rays, computed 
tomography or magnetic resonance imaging will become available as digital content. Of 
course, data protection concerns will be a tremendous challenge to be solved in this 
context. If issues related to confounding impede PSS based on electronic healthcare 
databases alone, large simple trials (Lesko and Mitchell 2012) and randomized database 
studies (van Staa et al. 2014, van Staa et al. 2012) constitute an auspicious opportunity in 
combining randomization and facilitated follow-up through electronic healthcare 
databases.  
In addition, this thesis focused on the correct assessment of safety outcomes in 
administrative claims data which is often neglected. It was highlighted that a high 
specificity of the case-algorithm of the outcome is essential in comparative drug safety 
studies. If a validation study with an external gold standard is not possible, a comparison 
of event rates to external data sources has been introduced as an opportunity to check 
the plausibility of a case-algorithm. Further, a detailed review of the available information 
(diagnoses, procedures, medications, etc.) was proposed as a useful approach to 
enhance the specificity of the case-algorithm based on administrative claims data. 
Furthermore, this thesis showed that the correct assessment of exposure based on 
pharmacy dispensing data in electronic healthcare databases can be critical in specific 
situations. This is particularly true for studies in the heterogeneous population of older 
patients in whom the prescribed dose may vary substantially and sporadic “as-needed” 
treatment is frequent. Thus, drug utilization should be investigated carefully before a 
safety study is planned and conducted. If exposure misclassification is likely, it should be 
evaluated whether the study can be performed and whether sensitivity analyses have to 
be conducted to test the consistency of the results under different assumptions of drug 
intake (i.e., frequency and dose). In the future, it will be crucial to perform external 
validation studies, for instance, with medical records to estimate the extent of exposure 
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misclassification and gain more detailed information on the prescribed dose if this 
information is not available in administrative claims databases.  
Another important topic in PSS among older patients is the effect of potentially interacting 
drugs. This thesis showed that polypharmacy and drug-drug interactions are frequent in 
older patients and may lead to a higher risk of ADRs. Although outcomes of drug-drug 
interactions itself are increasingly being studied, possible effect modification by potentially 
interacting drugs is rarely investigated. In future PSS in older patients, this should 
routinely be taken into account even though these drugs are often not independently 
associated with the outcome.  
Finally, time-related biases have been pointed out as an important threat to the credibility 
of drug safety studies based on electronic healthcare databases. As outlined in this thesis, 
these forms of biases can be avoided by using an appropriate study design. 
In the near future, the need for PSS after marketing approval will substantially grow, since 
post-authorization safety studies are commonly required in risk management plans which 
have to be submitted at the time of application for a marketing authorization. Because 
individual electronic healthcare databases are often too small, multidatabase studies such 
as in the SAFEGUARD project and large research networks, e.g., the Sentinel Initiative of 
the U.S. Food and Drug Administration (U.S. Food and Drug Administration 2010) or the 
Canadian Network for Observational Studies of Drug Effects (Suissa et al. 2012) will 
become more important to answer research questions with regard to the safety of newly 
marketed drugs. Many of these studies will analyze the safety of drugs in older patients, 
whose proportion in the general population will continuously increase and who will use the 
majority of drugs in the following decades. In this context, this thesis illustrated 
opportunities to assess the safety of drugs after marketing approval essentially 
contributing to the understanding of potential pitfalls to be addressed to enhance the 
quality of future PSS. 
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